Cameco Corporation (CCJ)
NYSE: CCJ · Real-Time Price · USD
76.55
+1.96 (2.63%)
At close: Aug 6, 2025, 4:00 PM
77.21
+0.66 (0.86%)
After-hours: Aug 6, 2025, 7:57 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $85.82, which forecasts a 12.11% increase in the stock price over the next year. The lowest target is $75.27 and the highest is $110.
Price Target: $85.82 (+12.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $100 → $110 | Buy | Maintains | $100 → $110 | +43.70% | Aug 1, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $90 → $100 | Buy | Maintains | $90 → $100 | +30.63% | Jun 20, 2025 |
| GLJ Research | GLJ Research | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | -1.67% | Jun 12, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $65 → $78 | Strong Buy | Maintains | $65 → $78 | +1.89% | Jun 11, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | -15.09% | May 20, 2025 |
Financial Forecast
Revenue This Year
3.41B
from 3.14B
Increased by 8.81%
Revenue Next Year
3.74B
from 3.41B
Increased by 9.50%
EPS This Year
1.48
from 0.39
Increased by 280.22%
EPS Next Year
2.20
from 1.48
Increased by 48.29%
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.8B | 4.5B | 5.0B |
| Avg | 3.4B | 3.7B | 3.9B |
| Low | 3.1B | 3.3B | 3.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 21.0% | 31.4% | 34.9% |
| Avg | 8.8% | 9.5% | 5.7% |
| Low | -0.3% | -4.1% | -8.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.01 | 3.32 | 3.28 |
| Avg | 1.48 | 2.20 | 2.53 |
| Low | 0.90 | 1.53 | 1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 414.2% | 123.8% | 49.0% |
| Avg | 280.2% | 48.3% | 14.9% |
| Low | 131.2% | 3.1% | -9.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.